BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 26123252)

  • 1. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
    Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV
    Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
    Dantuma NP; Herzog LK
    Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
    Paulino R; Nóbrega C
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
    Chen ZS; Huang X; Talbot K; Chan HYE
    Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
    Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases.
    Potapenko A; Davidson JM; Lee A; Laird AS
    Biochem J; 2024 Mar; 481(6):461-480. PubMed ID: 38497605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
    Raj K; Akundi RS
    Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FipoQ/FBXO33, a Cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein.
    Chen ZS; Wong AKY; Cheng TC; Koon AC; Chan HYE
    J Neurochem; 2019 Jun; 149(6):781-798. PubMed ID: 30685895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila melanogaster.
    Ristic G; Sutton JR; Libohova K; Todi SV
    Neurobiol Dis; 2018 Aug; 116():78-92. PubMed ID: 29704548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Planning Future Clinical Trials for Machado-Joseph Disease.
    Saute JAM; Jardim LB
    Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3.
    Johnson SL; Libohova K; Blount JR; Sujkowski AL; Prifti MV; Tsou WL; Todi SV
    Neurobiol Dis; 2021 Dec; 160():105516. PubMed ID: 34563642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry analyses of normal and polyglutamine expanded ataxin-3 reveal novel interaction partners involved in mitochondrial function.
    Kristensen LV; Oppermann FS; Rauen MJ; Fog K; Schmidt T; Schmidt J; Harmuth T; Hartmann-Petersen R; Thirstrup K
    Neurochem Int; 2018 Jan; 112():5-17. PubMed ID: 29111377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation.
    Johnson SL; Ranxhi B; Libohova K; Tsou WL; Todi SV
    Elife; 2020 Sep; 9():. PubMed ID: 32955441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.
    Watchon M; Yuan KC; Mackovski N; Svahn AJ; Cole NJ; Goldsbury C; Rinkwitz S; Becker TS; Nicholson GA; Laird AS
    J Neurosci; 2017 Aug; 37(32):7782-7794. PubMed ID: 28687604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyglutamine expansion of ataxin-3 alters its degree of ubiquitination and phosphorylation at specific sites.
    Kristensen LV; Oppermann FS; Rauen MJ; Hartmann-Petersen R; Thirstrup K
    Neurochem Int; 2017 May; 105():42-50. PubMed ID: 28065793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.
    Watchon M; Robinson KJ; Luu L; An Y; Yuan KC; Plenderleith SK; Cheng F; Don EK; Nicholson GA; Lee A; Laird AS
    FASEB J; 2024 Jan; 38(2):e23429. PubMed ID: 38258931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.